Published in J Comput Aided Mol Des on September 29, 2006
Molecular docking screens using comparative models of proteins. J Chem Inf Model (2009) 1.36
Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A. Pharmacol Rev (2011) 1.26
Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery. Comput Struct Biotechnol J (2013) 0.95
Endogenous opiates and behavior: 2006. Peptides (2007) 0.92
Drug design for ever, from hype to hope. J Comput Aided Mol Des (2012) 0.85
CoMFA analyses of C-2 position salvinorin A analogs at the kappa-opioid receptor provides insights into epimer selectivity. J Mol Graph Model (2010) 0.84
Recent advances in structure-based virtual screening of G-protein coupled receptors. AAPS J (2009) 0.79
Palladium-catalyzed transformations of salvinorin A, a neoclerodane diterpene from Salvia divinorum. Org Lett (2013) 0.78
Novel virtual screening approach for the discovery of human tyrosinase inhibitors. PLoS One (2014) 0.78
Identification, structure-activity relationships and molecular modeling of potent triamine and piperazine opioid ligands. Bioorg Med Chem (2009) 0.78
Virtual ligand screening against comparative protein structure models. Methods Mol Biol (2012) 0.78
Computational methods in drug discovery. Beilstein J Org Chem (2016) 0.78
Insights into subtype selectivity of opioid agonists by ligand-based and structure-based methods. J Mol Model (2010) 0.77
Chemical function-based pharmacophore generation of selective kappa-opioid receptor agonists by catalyst and phase. J Mol Model (2009) 0.75
CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res (1994) 392.47
The Protein Data Bank. Nucleic Acids Res (2000) 187.10
Comparative protein modelling by satisfaction of spatial restraints. J Mol Biol (1993) 64.61
Amino acid substitution matrices from protein blocks. Proc Natl Acad Sci U S A (1992) 61.33
The SWISS-PROT protein knowledgebase and its supplement TrEMBL in 2003. Nucleic Acids Res (2003) 52.80
Finishing the euchromatic sequence of the human genome. Nature (2004) 41.40
Comparative protein structure modeling of genes and genomes. Annu Rev Biophys Biomol Struct (2000) 17.81
Development and validation of a genetic algorithm for flexible docking. J Mol Biol (1997) 14.36
Drug discovery: a historical perspective. Science (2000) 8.15
The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J Mol Biol (2004) 7.38
Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science (1996) 6.50
Principles of docking: An overview of search algorithms and a guide to scoring functions. Proteins (2002) 5.79
Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev (2000) 4.98
X-ray structure of bacteriorhodopsin at 2.5 angstroms from microcrystals grown in lipidic cubic phases. Science (1997) 4.74
Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci U S A (2002) 4.34
ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett (1994) 3.78
Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry (2001) 3.62
Cloning of a delta opioid receptor by functional expression. Science (1992) 3.49
Molecular recognition and docking algorithms. Annu Rev Biophys Biomol Struct (2003) 3.40
Rhodopsin structure, dynamics, and activation: a perspective from crystallography, site-directed spin labeling, sulfhydryl reactivity, and disulfide cross-linking. Adv Protein Chem (2003) 3.28
A review of protein-small molecule docking methods. J Comput Aided Mol Des (2002) 3.25
The delta-opioid receptor: isolation of a cDNA by expression cloning and pharmacological characterization. Proc Natl Acad Sci U S A (1992) 2.84
Opioid receptors. Annu Rev Biochem (2004) 2.71
Structure-based virtual screening: an overview. Drug Discov Today (2002) 2.70
Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc Natl Acad Sci U S A (2001) 2.58
Molecular cloning and functional expression of a mu-opioid receptor from rat brain. Mol Pharmacol (1993) 2.54
Protein, lipid and water organization in bacteriorhodopsin crystals: a molecular view of the purple membrane at 1.9 A resolution. Structure (1999) 2.50
Virtual screening and fast automated docking methods. Drug Discov Today (2002) 2.48
Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. J Med Chem (2000) 2.35
Identification of G protein-coupled receptor genes from the human genome sequence. FEBS Lett (2002) 2.33
Salvia divinorum and salvinorin A: new pharmacologic findings. J Ethnopharmacol (1994) 2.28
Target validation of G-protein coupled receptors. Drug Discov Today (2002) 2.26
Role of the conserved NPxxY(x)5,6F motif in the rhodopsin ground state and during activation. Proc Natl Acad Sci U S A (2003) 2.21
Neoclerodane diterpenes as a novel scaffold for mu opioid receptor ligands. J Med Chem (2005) 2.13
Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther (2004) 1.97
Differential interaction of spin-labeled arrestin with inactive and active phosphorhodopsin. Proc Natl Acad Sci U S A (2006) 1.94
Protein-based virtual screening of chemical databases. II. Are homology models of G-Protein Coupled Receptors suitable targets? Proteins (2003) 1.93
Comparison of pharmacological activities of three distinct kappa ligands (Salvinorin A, TRK-820 and 3FLB) on kappa opioid receptors in vitro and their antipruritic and antinociceptive activities in vivo. J Pharmacol Exp Ther (2004) 1.89
Recent advances in molecular recognition and signal transduction of active peptides: receptors for opioid peptides. Cell Mol Neurobiol (1995) 1.84
Synthesis and in vitro pharmacological studies of new C(2) modified salvinorin A analogues. Bioorg Med Chem Lett (2005) 1.79
Studies toward the pharmacophore of salvinorin A, a potent kappa opioid receptor agonist. J Med Chem (2005) 1.78
Cloning and functional comparison of kappa and delta opioid receptors from mouse brain. Proc Natl Acad Sci U S A (1993) 1.77
Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J (1996) 1.74
High-throughput docking for lead generation. Curr Opin Chem Biol (2001) 1.74
Synthesis and in vitro pharmacological evaluation of salvinorin A analogues modified at C(2). Bioorg Med Chem Lett (2005) 1.60
Salvia divinorum and the unique diterpene hallucinogen, Salvinorin (divinorin) A. J Psychoactive Drugs (1995) 1.56
Changes in interhelical hydrogen bonding upon rhodopsin activation. J Mol Biol (2005) 1.51
Nociceptin/orphanin FQ and the opioid receptor-like ORL1 receptor. Eur J Pharmacol (1997) 1.51
Modelling G-protein-coupled receptors for drug design. Biochim Biophys Acta (1999) 1.50
Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.). J Ethnopharmacol (1983) 1.49
Integrating virtual screening in lead discovery. Curr Opin Chem Biol (2004) 1.48
Cloning and pharmacological characterization of a rat kappa opioid receptor. Proc Natl Acad Sci U S A (1993) 1.47
G protein-coupled receptors: in silico drug discovery in 3D. Proc Natl Acad Sci U S A (2004) 1.43
Kappa opioid antagonists: past successes and future prospects. AAPS J (2005) 1.41
Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. J Med Chem (2005) 1.41
Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. FEBS Lett (1994) 1.39
Functional microdomains in G-protein-coupled receptors. The conserved arginine-cage motif in the gonadotropin-releasing hormone receptor. J Biol Chem (1998) 1.37
Molecular cloning of a rat kappa opioid receptor reveals sequence similarities to the mu and delta opioid receptors. Biochem J (1993) 1.34
Synthesis and in vitro pharmacological studies of C(4) modified salvinorin A analogues. Bioorg Med Chem Lett (2005) 1.34
G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr Opin Drug Discov Devel (2001) 1.33
Structural origins of constitutive activation in rhodopsin: Role of the K296/E113 salt bridge. Proc Natl Acad Sci U S A (2004) 1.32
Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. J Med Chem (2005) 1.28
Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. J Med Chem (2004) 1.28
A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. Mol Pharmacol (1994) 1.25
Rhodopsin crystal: new template yielding realistic models of G-protein-coupled receptors? Trends Pharmacol Sci (2003) 1.23
Homology modeling of opioid receptor-ligand complexes using experimental constraints. AAPS J (2005) 1.18
Identification of an agonist-induced conformational change occurring adjacent to the ligand-binding pocket of the M(3) muscarinic acetylcholine receptor. J Biol Chem (2005) 1.17
Related contribution of specific helix 2 and 7 residues to conformational activation of the serotonin 5-HT2A receptor. J Biol Chem (1995) 1.16
Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. J Mol Biol (2003) 1.13
Identification of the molecular mechanisms by which the diterpenoid salvinorin A binds to kappa-opioid receptors. Biochemistry (2005) 1.13
Primary structures and expression from cDNAs of rat opioid receptor delta- and mu-subtypes. FEBS Lett (1993) 1.13
Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist. Pharmacol Biochem Behav (2006) 1.12
Structure-activity relationships of G protein-coupled receptors. Arch Med Res (2000) 1.08
Statistical potentials and scoring functions applied to protein-ligand binding. Curr Opin Struct Biol (2001) 1.03
Selected concepts and investigations in compound classification, molecular descriptor analysis, and virtual screening. J Chem Inf Comput Sci (2001) 1.00
2- and 8-alkynyladenosines: conformational studies and docking to human adenosine A3 receptor can explain their different biological behavior. J Mol Graph Model (2003) 0.97
Salvinorin A: a novel and highly selective kappa-opioid receptor agonist. Life Sci (2004) 0.95
Isolation of a human kappa opioid receptor cDNA from placenta. Biochem Biophys Res Commun (1994) 0.91
A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist. FEBS J (2006) 0.90
Heavier-than-air flying machines are impossible. FEBS Lett (2004) 0.90
Evaluation of the CASP2 docking section. Proteins (1997) 0.90
Structure-based drug design: computational advances. Annu Rev Pharmacol Toxicol (1997) 0.90
Acute physiologic and chronic histologic changes in rats and mice exposed to the unique hallucinogen salvinorin A. J Psychoactive Drugs (2003) 0.89
Crystal structure of rhodopsin: a G protein-coupled receptor. Palczewski K,*(1) kumasaka T, hori T, behnke CA, motoshima H, fox BA, trong IL, teller DC, okada T, stenkamp RE, yamamoto M, miyano M. Science 2000;289:739-745 Am J Ophthalmol (2000) 0.87
A comparison of the pharmacophore identification programs: Catalyst, DISCO and GASP. J Comput Aided Mol Des (2003) 0.87
Molecular modeling study of the editing active site of Escherichia coli leucyl-tRNA synthetase: two amino acid binding sites in the editing domain. Proteins (2004) 0.87
Scoring functions: a view from the bench. J Comput Aided Mol Des (1999) 0.83
Identification of a human delta opioid receptor: cloning and expression. Life Sci (1994) 0.80
Ligand identification for G-protein-coupled receptors: a lead generation perspective. Curr Opin Chem Biol (2004) 0.80
Chemical structures and biological activities of non-peptide selective kappa opioid ligands. Prog Med Chem (1992) 0.79
High-throughput and virtual screening: core lead discovery technologies move towards integration. Drug Discov Today (2000) 0.78
Lead generation using pharmacophore mapping and three-dimensional database searching: application to muscarinic M(3) receptor antagonists. J Med Chem (1999) 0.78
Dissecting G-protein-coupled receptors: structure, function, and ligand interaction. Chembiochem (2002) 0.77
Identification of endogenous surrogate ligands for human P2Y receptors through an in silico search. J Pharmacol Sci (2004) 0.76
The conformational switch in 7-transmembrane receptors: the muscarinic receptor paradigm. Eur J Pharmacol (1999) 0.75
High-throughput assays using a luciferase-expressing replicon, virus-like particles, and full-length virus for West Nile virus drug discovery. Antimicrob Agents Chemother (2005) 1.73
Triaryl pyrazoline compound inhibits flavivirus RNA replication. Antimicrob Agents Chemother (2006) 1.72
Sigma receptor agonists: receptor binding and effects on mesolimbic dopamine neurotransmission assessed by microdialysis. Biol Psychiatry (2010) 1.39
Self-treatment of opioid withdrawal using kratom (Mitragynia speciosa korth). Addiction (2008) 1.32
Opioid receptors and legal highs: Salvia divinorum and Kratom. Clin Toxicol (Phila) (2008) 1.28
Targeting the methyl erythritol phosphate (MEP) pathway for novel antimalarial, antibacterial and herbicidal drug discovery: inhibition of 1-deoxy-D-xylulose-5-phosphate reductoisomerase (DXR) enzyme. Curr Pharm Des (2007) 1.26
Identification of compounds with anti-West Nile Virus activity. J Med Chem (2006) 1.19
Cation-pi interactions: an energy decomposition analysis and its implication in delta-opioid receptor-ligand binding. J Am Chem Soc (2002) 1.16
N-naphthoyl-beta-naltrexamine (NNTA), a highly selective and potent activator of μ/kappa-opioid heteromers. Proc Natl Acad Sci U S A (2011) 1.05
Sigma receptors and cocaine abuse. Curr Top Med Chem (2011) 1.02
Mitragyna speciosa, a psychoactive tree from Southeast Asia with opioid activity. Curr Top Med Chem (2011) 0.99
A novel substituted piperazine, CM156, attenuates the stimulant and toxic effects of cocaine in mice. J Pharmacol Exp Ther (2010) 0.98
Conversion of a highly selective sigma-1 receptor-ligand to sigma-2 receptor preferring ligands with anticocaine activity. J Med Chem (2008) 0.97
Acridine-based agents with topoisomerase II activity inhibit pancreatic cancer cell proliferation and induce apoptosis. J Med Chem (2007) 0.97
Toward a structure-based model of salvinorin A recognition of the kappa-opioid receptor. J Med Chem (2008) 0.97
Molecular recognition of opioid receptor ligands. AAPS J (2006) 0.95
Determination of mitragynine in rat plasma by LC-MS/MS: application to pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 0.94
Synthesis and pharmacological evaluation of 6-acetyl-3-(4-(4-(4-fluorophenyl)piperazin-1-yl)butyl)benzo[d]oxazol-2(3H)-one (SN79), a cocaine antagonist, in rodents. AAPS J (2011) 0.94
Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity. Bioorg Med Chem (2006) 0.93
A unique binding epitope for salvinorin A, a non-nitrogenous kappa opioid receptor agonist. FEBS J (2006) 0.90
The hallucinogen derived from Salvia divinorum, salvinorin A, has kappa-opioid agonist discriminative stimulus effects in rats. Neuropharmacology (2007) 0.90
Early development of sigma-receptor ligands. Future Med Chem (2011) 0.90
CM156, a high affinity sigma ligand, attenuates the stimulant and neurotoxic effects of methamphetamine in mice. Neuropharmacology (2011) 0.89
Pharmacological evaluation of SN79, a sigma (σ) receptor ligand, against methamphetamine-induced neurotoxicity in vivo. Eur Neuropsychopharmacol (2012) 0.89
SN79, a sigma receptor ligand, blocks methamphetamine-induced microglial activation and cytokine upregulation. Exp Neurol (2013) 0.88
Phytochemical characterization of the leaves of Mitragyna speciosa grown in U.S.A. Nat Prod Commun (2009) 0.87
The evaluation of AZ66, an optimized sigma receptor antagonist, against methamphetamine-induced dopaminergic neurotoxicity and memory impairment in mice. Int J Neuropsychopharmacol (2012) 0.86
Opioid receptor function in social attachment in young domestic fowl. Behav Brain Res (2005) 0.85
CM156, a sigma receptor ligand, reverses cocaine-induced place conditioning and transcriptional responses in the brain. Pharmacol Biochem Behav (2011) 0.83
Specific cross-linking of Lys233 and Cys235 in the mu opioid receptor by a reporter affinity label. Biochemistry (2005) 0.83
Novel acridine-based compounds that exhibit an anti-pancreatic cancer activity are catalytic inhibitors of human topoisomerase II. Eur J Pharmacol (2008) 0.83
Ultra-performance liquid chromatography tandem mass spectrometry method for the determination of AZ66, a sigma receptor ligand, in rat plasma and its application to in vivo pharmacokinetics. Biomed Chromatogr (2013) 0.82
Chemical function-based pharmacophore development for novel, selective kappa opioid receptor agonists. J Mol Graph Model (2008) 0.81
Determination of a highly selective mixed-affinity sigma receptor ligand, in rat plasma by ultra performance liquid chromatography mass spectrometry and its application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci (2011) 0.81
Herbal medicines for the management of opioid addiction: safe and effective alternatives to conventional pharmacotherapy? CNS Drugs (2011) 0.81
Synthesis and pharmacological characterization of a novel sigma receptor ligand with improved metabolic stability and antagonistic effects against methamphetamine. AAPS J (2011) 0.81
Structure-activity relationships of neuropeptide FF and related peptidic and non-peptidic derivatives. Peptides (2006) 0.81
Antidepressive effects of the κ-opioid receptor agonist salvinorin A in a rat model of anhedonia. Behav Pharmacol (2012) 0.81
Synthesis and evaluation of xanomeline analogs--probing the wash-resistant phenomenon at the M1 muscarinic acetylcholine receptor. Bioorg Med Chem (2007) 0.81
Evaluation of σ-1 receptor radioligand 18F-FTC-146 in rats and squirrel monkeys using PET. J Nucl Med (2013) 0.81
Quantitative three dimensional structure linear interaction energy model of 5'-O-[N-(salicyl)sulfamoyl]adenosine and the aryl acid adenylating enzyme MbtA. J Med Chem (2008) 0.80
A 96-well filtration method for radioligand binding analysis of σ receptor ligands. J Pharm Biomed Anal (2012) 0.80
Toward Mycobacterium tuberculosis DXR inhibitor design: homology modeling and molecular dynamics simulations. J Comput Aided Mol Des (2007) 0.79
Discovery of Imidazoquinolines with Toll-Like Receptor 7/8 Independent Cytokine Induction. ACS Med Chem Lett (2012) 0.79
Comparative protein modeling of 1-deoxy-D-xylulose-5-phosphate reductoisomerase enzyme from Plasmodium falciparum: a potential target for antimalarial drug discovery. J Chem Inf Model (2006) 0.78
Synthesis and characterization of [³H]-SN56, a novel radioligand for the σ₁ receptor. Eur J Pharmacol (2010) 0.78
Heteroatom analogues of hydrocodone: synthesis and biological activity. J Org Chem (2013) 0.78
Structure-activity relationship analysis of imidazoquinolines with Toll-like receptors 7 and 8 selectivity and enhanced cytokine induction. J Med Chem (2014) 0.78
Nonpeptide ligands of neuropeptide FF: current status and structural insights. Future Med Chem (2012) 0.77
Synthesis and cancer cell cytotoxicity of substituted xanthenes. Bioorg Med Chem (2010) 0.77
Novel acridine-based agents with topoisomerase II inhibitor activity suppress mesothelioma cell proliferation and induce apoptosis. Invest New Drugs (2011) 0.77
Beta-triketone inhibitors of plant p-hydroxyphenylpyruvate dioxygenase: modeling and comparative molecular field analysis of their interactions. J Agric Food Chem (2009) 0.77
Sigma receptor antagonists attenuate acute methamphetamine-induced hyperthermia by a mechanism independent of IL-1β mRNA expression in the hypothalamus. Eur J Pharmacol (2012) 0.77
Solution-phase parallel synthesis of spirohydantoins. J Comb Chem (2005) 0.77
Nonpeptide small molecule agonist and antagonist original leads for neuropeptide FF1 and FF2 receptors. J Med Chem (2014) 0.77
9-Amino acridine pharmacokinetics, brain distribution, and in vitro/in vivo efficacy against malignant glioma. Cancer Chemother Pharmacol (2012) 0.77
On the role of topoisomerase I in mediating the cytotoxicity of 9-aminoacridine-based anticancer agents. Bioorg Med Chem Lett (2009) 0.76
Molecular modeling of opioid receptor-ligand complexes. Prog Med Chem (2002) 0.76
σ Receptor antagonist attenuation of methamphetamine-induced neurotoxicity is correlated to body temperature modulation. Pharmacol Rep (2013) 0.76
Structure and stability of human telomeric G-quadruplex with preclinical 9-amino acridines. PLoS One (2013) 0.76
Development and validation of a UPLC-MS/MS method for the determination of 7-hydroxymitragynine, a μ-opioid agonist, in rat plasma and its application to a pharmacokinetic study. Biomed Chromatogr (2013) 0.75
Computational Study on the Conformations of Mitragynine and Mitragynaline. Theochem (2010) 0.75
Synthesis and pharmacological evaluation of indole-based sigma receptor ligands. Eur J Med Chem (2011) 0.75
Structure activity relationship study of benzo[d]thiazol-2(3H)one based σ receptor ligands. Bioorg Med Chem Lett (2013) 0.75
Melatonin related compounds inhibit lipid peroxidation during copper or free radical-induced LDL oxidation. J Pineal Res (2002) 0.75
Spectrophotometric determination and computational evaluation of the rates of hydrolysis of 9-amino-substituted acridines. J Chem Inf Model (2006) 0.75
Opioid receptor-like 1 (ORL1) molecular "road map" to understanding ligand interaction and selectivity. Curr Top Med Chem (2005) 0.75
Ligand macromolecule interactions: theoretical principles of molecular recognition. Methods Mol Biol (2009) 0.75
o-Naphthalenedicarboxaldehyde derivative of 7'-aminonaltrindole as a selective delta-opioid receptor affinity label. J Med Chem (2007) 0.75
Strategies to treat substance abuse and addiction. Curr Top Med Chem (2011) 0.75
Inhibition of choline uptake by N-cyclohexylcholine, a high affinity ligand for the choline transporter at the blood-brain barrier. J Drug Target (2005) 0.75
SAR analysis of new dual targeting fluoroquinolones. Implications of the benzenesulfonyl group. Med Chem (2012) 0.75